SMT C1100 regulatory update

EMEA's Committee for Orphan Medical Products (COMP) issued a positive opinion to grant Orphan Drug designation for SMT C1100 to treat Duchenne muscular dystrophy (DMD). Summit granted BioMarin exclusi...